Posted by Michael Wonder on 11 Apr 2022
Orchard Therapeutics announces reimbursement agreement making Libmeldy available for all eligible MLD patients in Italy
11 April 2022 - Orchard Therapeutics today announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco (AIFA), to enable access to Libmeldy (atidarsagene autotemcel) for all children with metachromatic leukodystrophy who fall within the scope of the European marketing authorisation.
The news marks the second reimbursement agreement to cover all eligible metachromatic leukodystrophy patients that Orchard has reached with a European market this year.
